Guanfacine treatment of cognitive impairment in schizophrenia

Joseph I. Friedman, David N. Adler, Humberto D. Temporini, Eileen Kemether, Philip D. Harvey, Leonard White, Michael Parrella, Kenneth L. Davis

Research output: Contribution to journalArticle

103 Scopus citations

Abstract

Norepinephrine plays a significant role in the working memory functions of the prefrontal cortex by its actions at alpha-2a noradrenergic receptors. Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate. In the present study the effect of guanfacine adjunctive treatment to neuroleptics on the cognitive performance of schizophrenic patients was investigated in a four week, placebo-controlled, double-blind, parallel design trial. The primary analyses revealed no significant differences between guanfacine and placebo treatment; however, exploratory non-parametric statistics revealed some significant and some trend differences between guanfacine and placebo on spatial working memory test performance and CPT reaction time in those subjects treated with atypical neuroleptics.

Original languageEnglish (US)
Pages (from-to)402-409
Number of pages8
JournalNeuropsychopharmacology
Volume25
Issue number3
DOIs
StatePublished - Sep 3 2001
Externally publishedYes

Keywords

  • Clinical Trial
  • Cognitive
  • Guanfacine
  • Norepinephrine
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Guanfacine treatment of cognitive impairment in schizophrenia'. Together they form a unique fingerprint.

  • Cite this

    Friedman, J. I., Adler, D. N., Temporini, H. D., Kemether, E., Harvey, P. D., White, L., Parrella, M., & Davis, K. L. (2001). Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology, 25(3), 402-409. https://doi.org/10.1016/S0893-133X(01)00249-4